|Bid||105.00 x 200|
|Ask||109.86 x 200|
|Day's Range||108.22 - 108.61|
|52 Week Range||85.37 - 108.90|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.08%|
In 2Q17, BioMarin Pharmaceuticals’ (BMRN) Aldurazyme generated revenues of around $20 million, which was a ~6% increase on a year-over-year (or YoY) basis.
In 2Q17, Jazz Pharmaceuticals’ (JAZZ) Defitelio generated revenues of ~$30 million, which represents a ~10% fall YoY and a ~17% fall QoQ.
To expand Xyrem’s addressable market, JAZZ has been evaluating the efficacy of Xyrem in pediatric narcolepsy patients with cataplexy and excessive sleepiness.
Investors pull billions of dollars from the largest exchange-traded fund tracking the Nasdaq 100, the latest indication that investors are looking to take profits from a group that have led the market’s ...
Bioverativ (BIVV) plans to improve compliance rates for hemophilia patients further by launching therapies with lower dosage frequency.
Many of the largest exchange-traded funds focus on U.S. large-cap stocks. For example, the two largest ETFs, and three of the five biggest, track the S&P 500. While the S&P 500 is the benchmark U.S. equity ...
Deckers Outdoor (DECK) reported fiscal 2Q17 net sales of $485.9 million, a fall of 0.21% from the net sales of $486.9 million in fiscal 2Q16.
On January 3, 2017, Jefferies downgraded Steven Madden’s rating from "buy" to “hold” and set the stock’s price target at $37.00 per share.
Price movement Deckers Outdoor (DECK) has a market cap of $1.9 billion. It rose 4.9% to close at $60.17 per share on November 11, 2016. The stock’s weekly, monthly, and…